When to Start, When to Switch, and What Dosing Should Be Used With Anti-VEGF Therapy for nAMD
This case consult with Drs. Borkar and Do presents a patient with newly diagnosed vision loss. After reviewing the diagnosis, these retina specialists discuss intravitreal anti-VEGF treatment options including the more durable anti-VEGF therapies, faricimab and aflibercept 8 mg. They consider approaches to selecting an agent, treatment initiation, criteria for changing dosing intervals, and switching therapies.
*Free for AAO Members